OverviewSuggest Edit

Vitality Biopharma focuses on the development of cannabinoids for the treatment of neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis. Its products in pipeline include Cannabosides - VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides - VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse and Huntington's disease.

TypePublic
Founded2012
HQLos Angeles, CA, US
Websitevitality.bio

Latest Updates

Employees (est.) (Jul 2019)8(+15%)
Revenue (FY, 2019)$258.3 K(+153%)
Share Price (Jul 2021)$0.2(+27%)
Cybersecurity ratingAMore

Key People/Management at Vitality Biopharma

Edward Feighan

Edward Feighan

Executive Chairman
Michael Cavanaugh

Michael Cavanaugh

CEO, Director
Richard Celeste

Richard Celeste

Director
Richard McKilligan

Richard McKilligan

CFO and Counsel
Brandon Zipp

Brandon Zipp

Chief Science Officer, Scientific Co-Founder
Show more

Vitality Biopharma Office Locations

Vitality Biopharma has an office in Los Angeles
Los Angeles, CA, US (HQ)
1901 Avenue of the Stars 2nd Floor
Show all (1)

Vitality Biopharma Financials and Metrics

Vitality Biopharma Revenue

Vitality Biopharma's revenue was reported to be $258.29 k in FY, 2019
USD

Net income (Q3, 2021)

693.0k

EBIT (Q3, 2021)

(466.5k)

Market capitalization (15-Jul-2021)

9.9m

Closing stock price (15-Jul-2021)

0.2

Cash (31-Dec-2020)

1.4m

EV

8.5m
Vitality Biopharma's current market capitalization is $9.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

248.3k163.4k102.4k258.3k

Revenue growth, %

(34%)(37%)

Cost of goods sold

149.5k108.3k77.9k

Gross profit

98.9k55.1k24.5k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q2, 2020Q3, 2020Q1, 2021Q3, 2021

Revenue

46.4k45.9k39.7k31.0k19.3k36.5k94.8k

Cost of goods sold

25.1k20.9k19.9k17.5k17.0k14.7k

Gross profit

21.3k25.0k19.8k13.5k2.3k21.8k

Gross profit Margin, %

46%54%50%44%12%60%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

532.2k392.5k1.4m389.7k95.4k1.2m656.3k6.0m2.4m

Accounts Receivable

61.6k30.4k19.2k13.8k19.4k

Prepaid Expenses

1.2k9.1k10.6k2.5k2.5k3.1k3.1k50.5k15.7k

Inventories

8.5k6.5k
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q2, 2020Q3, 2020Q1, 2021Q3, 2021

Cash

394.054.5k16.6k892.1k596.0k1.2m551.3k1.8m830.1k1.8m1.1m1.2m692.7k208.1k20.5k33.7k153.8k815.5k1.4m336.7k7.5m4.0m3.1m1.8m1.4m

Accounts Receivable

27.9k39.4k39.7k43.3k42.9k76.8k39.2k27.9k32.2k20.2k13.5k20.1k45.9k

Prepaid Expenses

612.03.6k3.2k229.5k26.2k8.8k10.5k9.3k9.5k21.5k9.5k2.5k2.5k2.5k3.1k3.1k3.1k8.1k21.3k19.1k13.2k13.2k13.2k

Inventories

15.9k19.4k34.8k8.5k9.4k7.9k6.5k6.5k6.5k
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(1.3m)(2.7m)(4.2m)(4.0m)(141.3k)(5.2m)(4.3m)(13.1m)(4.4m)

Depreciation and Amortization

12.3k

Inventories

(8.5k)2.0k6.5k

Accounts Payable

71.6k32.5k107.7k4.1k110.9k158.1k(173.2k)285.9k221.6k
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q2, 2020Q3, 2020Q1, 2021Q3, 2021

Net Income

(8.9k)(84.4k)(43.7k)(426.5k)(1.8m)(899.3k)(1.7m)(2.7m)(655.8k)(2.1m)(3.2m)215.6k719.9k636.3k(439.4k)(1.6m)(4.1m)(2.0m)(3.2m)(2.4m)(3.6m)(2.8m)(3.6m)(740.2k)(520.2k)

Depreciation and Amortization

203.7k

Inventories

(15.9k)(19.4k)(34.8k)(954.0)612.0

Accounts Payable

(1.7k)(25.4k)143.9k70.3k(1.1k)194.2k31.3k73.5k7.4k25.8k49.5k27.4k(12.0k)62.1k129.7k(93.6k)(327.9k)114.2k(43.1k)473.4k292.5k(106.0k)(178.0k)
Show all financial metrics

Vitality Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Vitality Biopharma Online and Social Media Presence

Embed Graph

Vitality Biopharma News and Updates

Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives

CLEVELAND, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a drug development company dedicated to unlocking the unique therapeutic powers of cannabinoids, today announced that it has retained DelMorgan & Co., an internationally recogniz…

Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors

LOS ANGELES, April 25, 2019 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious n…

Vitality Biopharma Appoints Former Ohio Governor Richard F. Celeste to Board

LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious ne…

Vitality Biopharma Announces Corporate Updates and Completion of an SEC Examination

LOS ANGELES, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neu…

Vitality Biopharma Scientific Co-Founder to Present Recent Data at CannMed Medical Conference in Los Angeles

Dr. Brandon Zipp to discuss outlook for Vitality’s VBX-100 THC prodrug in scientific presentation held at UCLA Dr. Brandon Zipp to discuss outlook for Vitality’s VBX-100 THC prodrug in scientific presentation held at UCLA

Vitality Biopharma THC Prodrug VBX-100 Demonstrates Positive Safety Results

-  During safety pharmacology screening Vitality’s THC prodrug demonstrates no signs of adverse or off-target effects -  During safety pharmacology screening Vitality’s THC prodrug demonstrates no signs of adverse or off-target effects 

Vitality Biopharma Blogs

8-K – Current report

Filed: 2019-04-25 AccNo: 0001493152-19-005939 Size: 40 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits

Vitality Biopharma Board Update

CLEVELAND, OHIO – (April 27, 2020)— Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, today announced that Dr. Anthony Maida has decided to resign from its Board of Director…

Vitality Biopharma Welcomes New Executive Management Team

– Appointment of Current Director Michael Cavanaugh as Interim Chief Executive Officer – – Promotion of Current Controller and Counsel Richard McKilligan to Chief Financial Officer – LOS ANGELES, CA (MARKETWIRED – May 14, 2019) – Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”),…

Vitality Biopharma to Present at the 11th Annual LD Micro Main Event

LOS ANGELES, CA – (GLOBE NEWSWIRE – December 3, 2018) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and in…

Vitality Biopharma Receives $8.5 Million Common Stock Financing

Financing to support company at least into 2020 and for the initiation of multiple Phase 2 clinical trials LOS ANGELES, CA – (October 23, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prod…
Show more

Vitality Biopharma Frequently Asked Questions

  • When was Vitality Biopharma founded?

    Vitality Biopharma was founded in 2012.

  • Who are Vitality Biopharma key executives?

    Vitality Biopharma's key executives are Edward Feighan, Michael Cavanaugh and Richard Celeste.

  • How many employees does Vitality Biopharma have?

    Vitality Biopharma has 8 employees.

  • Who are Vitality Biopharma competitors?

    Competitors of Vitality Biopharma include CSPC Pharmaceutical Group, Sandoz and Alkem Laboratories.

  • Where is Vitality Biopharma headquarters?

    Vitality Biopharma headquarters is located at 1901 Avenue of the Stars 2nd Floor, Los Angeles.

  • Where are Vitality Biopharma offices?

    Vitality Biopharma has an office in Los Angeles.

  • How many offices does Vitality Biopharma have?

    Vitality Biopharma has 1 office.